280 related articles for article (PubMed ID: 22086206)
1. Biological aspects of angiogenesis in multiple myeloma.
Otjacques E; Binsfeld M; Noel A; Beguin Y; Cataldo D; Caers J
Int J Hematol; 2011 Dec; 94(6):505-18. PubMed ID: 22086206
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis in multiple myeloma.
Vacca A; Ria R; Reale A; Ribatti D
Chem Immunol Allergy; 2014; 99():180-96. PubMed ID: 24217610
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.
Martin SK; Diamond P; Williams SA; To LB; Peet DJ; Fujii N; Gronthos S; Harris AL; Zannettino AC
Haematologica; 2010 May; 95(5):776-84. PubMed ID: 20015878
[TBL] [Abstract][Full Text] [Related]
4. Role of tumour angiogenesis in haematological malignancies.
Medinger M; Passweg J
Swiss Med Wkly; 2014; 144():w14050. PubMed ID: 25375891
[TBL] [Abstract][Full Text] [Related]
5. [Link between osteoclastogenesis, angiogenesis and myeloma expansion].
Abe M
Clin Calcium; 2008 Apr; 18(4):473-9. PubMed ID: 18379029
[TBL] [Abstract][Full Text] [Related]
6. New Insights in Anti-Angiogenesis in Multiple Myeloma.
Ribatti D; Vacca A
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30002349
[TBL] [Abstract][Full Text] [Related]
7. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis.
Giuliani N; Colla S; Lazzaretti M; Sala R; Roti G; Mancini C; Bonomini S; Lunghi P; Hojden M; Genestreti G; Svaldi M; Coser P; Fattori PP; Sammarelli G; Gazzola GC; Bataille R; Almici C; Caramatti C; Mangoni L; Rizzoli V
Blood; 2003 Jul; 102(2):638-45. PubMed ID: 12649156
[TBL] [Abstract][Full Text] [Related]
8. Macrophages in multiple myeloma.
Ribatti D; Moschetta M; Vacca A
Immunol Lett; 2014 Oct; 161(2):241-4. PubMed ID: 24370642
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis in multiple myeloma.
Sezer O; Niemöller K; Jakob C; Heider U
Leuk Res; 2002 Jul; 26(7):701-2. PubMed ID: 12008091
[No Abstract] [Full Text] [Related]
10. JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
Fan F; Malvestiti S; Vallet S; Lind J; Garcia-Manteiga JM; Morelli E; Jiang Q; Seckinger A; Hose D; Goldschmidt H; Stadlbauer A; Sun C; Mei H; Pecherstorfer M; Bakiri L; Wagner EF; Tonon G; Sattler M; Hu Y; Tassone P; Jaeger D; Podar K
Leukemia; 2021 Dec; 35(12):3509-3525. PubMed ID: 34007044
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis in multiple myeloma.
Jakob C; Sterz J; Zavrski I; Heider U; Kleeberg L; Fleissner C; Kaiser M; Sezer O
Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic effect of bortezomib in patients with multiple myeloma.
Politou M; Naresh K; Terpos E; Crawley D; Lampert I; Apperley JF; Rahemtulla A
Acta Haematol; 2005; 114(3):170-3. PubMed ID: 16227683
[No Abstract] [Full Text] [Related]
13. Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.
Lamanuzzi A; Saltarella I; Ferrucci A; Ria R; Ruggieri S; Racanelli V; Rao L; Annese T; Nico B; Vacca A; Ribatti D
Oncotarget; 2016 Mar; 7(12):14510-21. PubMed ID: 26919105
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
15. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis and vasculogenesis in multiple myeloma: role of inflammatory cells.
Vacca A; Ribatti D
Recent Results Cancer Res; 2011; 183():87-95. PubMed ID: 21509681
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin Promotes Angiogenesis and Disease Progression in Patients with Multiple Myeloma.
Lamanuzzi A; Saltarella I; Frassanito MA; Ribatti D; Melaccio A; Desantis V; Solimando AG; Ria R; Vacca A
Am J Pathol; 2021 Apr; 191(4):748-758. PubMed ID: 33516787
[TBL] [Abstract][Full Text] [Related]
18. Regulatory role of DEPTOR‑mediated cellular autophagy and mitochondrial reactive oxygen species in angiogenesis in multiple myeloma.
Wang J; Chen J; Qiu D; Zeng Z
Int J Mol Med; 2021 Feb; 47(2):643-658. PubMed ID: 33416146
[TBL] [Abstract][Full Text] [Related]
19. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.
Li S; Fu J; Lu C; Mapara MY; Raza S; Hengst U; Lentzsch S
Mol Cancer Ther; 2016 Apr; 15(4):711-9. PubMed ID: 26939700
[TBL] [Abstract][Full Text] [Related]
20. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
